Arcinova is a specialist CDMO providing expert drug substance and drug product development, including radiolabelling (14C), CMC strategy and GMP clinical trial material (with expertise in sterile and oral products).
Arcinova and Quotient Sciences operate as one integrated organisation delivering end-to-end drug development and clinical manufacturing solutions under two complementary brands.
Quotient Sciences extends these capabilities through clinical pharmacology, ADME studies, and adaptive clinical trial delivery through its industry-leading Translational Pharmaceutics® platform.
Together they combine chemistry, manufacturing, and clinical testing services within one organisation to streamline development, reduce timelines, and accelerate drug development.